TherapeuticsMD (TXMD) Misses Q4 EPS by 1c

TherapeuticsMD (NASDAQ: TXMD) reported Q4 EPS of ($0.10), $0.01 worse than the analyst estimate of ($0.09). Revenue for the quarter came in at $4.1 million versus the consensus estimate of $4.66 million.

For earnings history and earnings-related data on TherapeuticsMD (TXMD) click here.

You May Also Be Interested In

• Kroger (KR) Reports In-Line Q1 EPS, Beats on Revenue; Offers FY27 EPS Guidance
• Vail Resorts taps bankers for potential activist defense, Semafor reports
• John Wiley & Sons, Inc. (WLYB) Tops Q4 EPS by 12c; Offers Outlook